• P-ISSN2233-4203
  • E-ISSN2093-8950
  • ESCI, SCOPUS, KCI

Article Detail

Home > Article Detail
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

In Vitro Inhibitory Effect of Licoricidin on Human Cytochrome P450s

Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2014, v.5 no.3, pp.84-88
https://doi.org/10.5478/MSL.2014.5.3.84
Kim Sunju (Kyungpook National University)
O Heungchan (Kyungpook National University)
Kim Jeong Ah (Kyungpook National University)
Lee Seung Ho (Yeungnam University)
Lee Sangkyu (Kyungpook National University)
  • Downloaded
  • Viewed

Abstract

Licoricidin isolated from Glycyrrhiza uralensis is known to have anticancer, anti-nephritic, anti-Helicobacter pylori,and antibacterial effects. In this study, a cocktail probe assay and liquid chromatography-tandem mass spectrometry (LC-MS/MS) were used to investigate the modulating effect of licoricidin on cytochrome P450 (CYP) enzymes in human livermicrosomes. When licoricidin was incubated at 0-25 μM with CYP probes for 60 min at 37oC, it showed potent inhibitoryeffects on CYP2B6-catalyzed bupropion hydroxylation and CYP2C9-catalyzed diclofenac 4’-hydroxylation with half maximalinhibitory concentration (IC50) values of 3.4 and 4.0 μM, respectively. The inhibition mode of licoricidin was revealed as competitive,dose-dependent, and non-time-dependent, and following the pattern of Lineweaver-Burk plots. The inhibitory effect oflicoricidin has been confirmed in human recombinant cDNA-expressed CYP2B6 and 2C9 with IC50 values of 4.5 and 0.73 μM,respectively. In conclusion, this study has shown the potent inhibitory effect of licoricidin on CYP2B6 and CYP2C9 activitycould be important for predicting potential herb-drug interactions with substrates that mainly undergo CYP2B- and CYP2C9-mediated metabolism.

keywords
Licoricidin, LC-MRM, cytochrome P450, inhibition


Reference

1

Rendic, S.. (2002). . Drug Metab. Rev, 34, 83-.

2

Guengerich, F. P.. (1997). . J. Mol. Pharmacol, 51, 147-.

3

Spaggiari, D.. (2014). . J. Pharm. Biomed. Anal, , -.

4

Messier, C.. (2012). . Oral Dis, 18, 32-.

5

Park, S. Y.. (2010). . Br. J. Nutr, 104, 1272-.

6

Fukai, T.. (2002). . Life Sci, 71, 1449-.

7

Tanaka, Y.. (2001). . J. Nutr. Sci. Vitaminol, 47, 270-.

8

Fukai, T.. (2003). . Fitoterapia, 74, 720-.

9

La, V. D.. (2011). . J. Periodontol, 82, 122-.

10

Song, M.. (2013). . Food Chem. Toxicol, 59, 549-.

11

Mo, S. L.. (2009). . Curr. Drug Metab, 10, 730-.

12

Turpeinen, M.. (2006). . Curr. Drug Metab, 7, 705-.

13

Hirota, T.. (2013). . Drug Metab. Pharmacokinet, 28, 28-.

14

Steward, D. J.. (1997). . Pharmacogenetics, 7, 361-.

Submission Date
2014-07-28
Revised Date
2014-08-27
Accepted Date
2014-08-28
상단으로 이동

Mass Spectrometry Letters